8 news items
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
presentation, titled "A Phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46
FibroGen Shares Climb On Strong Q1 Sales
FGEN
7 May 24
data on FG-3246, our CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer and continued robust growth of our
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
ADTN
AMBC
AORT
7 May 24
Yigal Nochomovitz initiated coverage on Summit Therapeutics with a Buy rating and announced a price target of $7.
Hims & Hers
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
Reported compelling data from Phase 1 monotherapy study of FG-3246, a CD46 targeted antibody drug conjugate
FibroGen to Report First Quarter 2024 Financial Results
FGEN
29 Apr 24
been accepted for review by the China Health Authority. FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development
7pp 1iyfz
FGEN
24 Apr 24
-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant
jmez1kjar4t6bb5adkwrvzp fcjkybc9lmt622pb80pivseeo5y6k0eu
ABAT
ABIO
ACORQ
3 Apr 24
to Buy and announced a $6 price target.
Dave & Buster's Entertainment, Inc
0zpksje7zev6j04a9exr6duxiws6yvg31h4ljcwo7x
FGEN
2 Apr 24
of 1.2 mg/kg and higher is quite favorable and highlights the therapeutic potential of FG-3246 as a new ADC aimed at a novel target. These findings
- Prev
- 1
- Next